Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.63 |
| ▸ | CTSS | P25774 | 7/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17133720 | 1.00 | CTSK (0.63) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL17133688 | 0.95 | CTSK (0.58) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL22236519 | 0.92 | CTSS (0.63) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL17133715 | 0.92 | CTSK (0.60) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL17133689 | 0.90 | CA2 (0.56) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL17537317 | 0.90 | CA2 (0.56) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL17133745 | 0.90 | CTSK (0.64) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL17531098 | 0.90 | CTSK (0.74) | CTSKCTSSCTSBCTSL | |
| SCHEMBL17146997 | 0.90 | CTSK (0.64) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL17133683 | 0.89 | CA2 (0.56) | CTSKCTSSCTSBCTSLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2927212-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | Kyoto University (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CTSK 188/4885CTSS 273/4885CTSB 159/4885 |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KDM1A, DOT1L, KDM1B | CTSK 2479/4885CTSS 2069/4885CTSB 2460/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CTSK 188/4885CTSS 273/4885CTSB 159/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CTSK 188/4885CTSS 273/4885CTSB 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.